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Background. Intensification of antiretroviral therapy with raltegravir does not affect levels of residual human
immunodeficiency virus (HIV)-1 viremia, but it has led to increased levels of episomal HIV-1 DNA in some patients,
suggesting antiviral activity against otherwise unresponsive components of the viral reservoir. Effects of raltegravir on
host cells remain less well understood.
Methods. We used comprehensive and unbiased microarray-based transcriptional profiling to analyze gene ex-
pression changes in CD8+ T cells from participants in a randomized clinical trial (AIDS Clinical Trials Group
[ACTG] A5244) comparing raltegravir-intensified to nonintensified antiretroviral therapy.
Results. Although raltegravir intensification failed to induce statistically significant changes in HIV-1 DNA or
residual plasma viremia, we observed significant increases in the expression intensity of 121 host gene transcripts. In
functional annotations of these transcripts, we found that they were mainly involved in glucose and carbohydrate
metabolism, immune regulation, control of cell proliferation, and tumor suppression. Two of the raltegravir-responsive
gene transcripts were statistically correlated with levels of residual HIV-1 RNA, but none of the remaining 119 tran-
scripts were associated with immunologic or virologic characteristics of the study patients.
Conclusions. Together, these findings demonstrate that raltegravir intensification can induce previously unrecog-
nized, statistically significant gene expression changes in host CD8+ T lymphocytes.
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Combination antiretroviral therapy (ART) can effec-
tively suppress plasma levels of human immunodefi-
ciency virus (HIV)-1 replication below the threshold
of detection of commercial polymerase chain reaction
(PCR) assays, but residual HIV-1 viremia and a reser-
voir of latently infected HIV-1 cells remain detectable in
the majority of patients, and they contribute to viral
persistence despite treatment [1]. Whether residual,
low-level HIV-1 viremia in ART-treated patients reflects
ongoing complete cycles of viral replication, cell-to-cell
spread of HIV-1, or virus release from HIV-1 infected
cells is an ongoing debate; however, antiretroviral inten-
sification does not affect the levels of residual HIV-1 vi-
remia [2–5], and most [6–8], but not all [9], studies do
not find evidence of ongoing viral sequence evolution
in residual plasma HIV-1 RNA. Nevertheless, ART in-
tensified with raltegravir resulted in elevations of episom-
al 2-long terminal repeat (LTR) HIV-1 DNA in several
patients [5, 10], suggesting that ongoing HIV-1 replica-
tion can occur in some ART-treated patients. Although
effects of intensified ART on viral replication dynamics
have been investigated in detail, only limited information
is available regarding effects of raltegravir intensification
on host cells. In previous studies, intensification of ART
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with raltegravir resulted in some degree of reduction of immune
activation [2–4], which is inversely associated with reconstitution
of CD4+ T cells [11, 12] and the frequency of HIV-1-associated
comorbities [13, 14] in ART-treated individuals. However, effects
of raltegravir on immune activation were of limited statistical sig-
nificance, and not all studies showed an effect.
Transcriptional profiling allows for comprehensive high-
throughput assessments of gene expression patterns, and it
provides an opportunity to discover previously unrecognized
changes in host gene expression signatures associated with dis-
tinct disease entities or treatment interventions. In this study,
we used whole-genome transcriptional profiling to comprehen-
sively analyze gene expression changes in T lymphocytes from
patients participating in a randomized, placebo-controlled clin-
ical study that evaluated the effects of raltegravir intensification
in ART-treated patients [4] (AIDS Clinical Trials Group
[ACTG] A5244 [NCT00515827]). This placebo-controlled clin-
ical trial did not find evidence for an effect of raltegravir inten-
sification on residual HIV-1 viremia, CD4+ T cell-associated
total HIV-1 DNA, or 2-LTR HIV-1 DNA. In addition, there was
no influence of raltegravir intensification on immune activation
in CD8+ T cells or CD4+ T cells, defined by coexpression of
CD38 and human leukocyte antigen (HLA)-DR, although a
trend for a reduced percentage of CD38-positive cells in the
CD8+ T cell compartment after raltegravir intensification was
noted [4]. We hypothesized that despite the lack of a significant
effect on persistent viremia or conventional measures of CD8+
T cell activation, raltegravir intensification may be associated
with more subtle changes in gene expression and activation of
CD8+ T cells that can only be detected using an unbiased, com-
prehensive analytic approach. We chose to focus on transcrip-
tional changes in the CD8+ T compartment rather than the
CD4+ T compartment, because abnormal immune activation in




We performed whole-genome transcriptional profiling in iso-
lated CD8+ T cells from patients participating in ACTG study
A5244. In this study, 53 HIV-1-infected participants receiving
suppressive ART with plasma HIV-1 RNA <50 copies/mL but
detectable viremia by single-copy assay were randomized to
either add raltegravir (group A) or placebo (group B) to their
background ART regimen for 12 weeks; participants then
crossed over to the other therapy (placebo in group A; raltegra-
vir in group B) for 12 additional weeks while continuing pre-
study ART. Clinical and demographic characteristics of the 32
patients included in this study did not significantly differ from
the original study population (n = 53), and these characteristics
are summarized in Table 1.
Isolation of CD8 T Cells
Using an automated magnetic cell enrichment device that
isolates target cell populations with >95% purity, CD3/CD8-
positive T cells were isolated from peripheral blood mononu-
clear cell samples collected at baseline, week 12, and week
24 in 32 study subjects (n = 16 from Group A, n = 16 from
group B).
Gene Microarrays
After mRNA extraction from the purified cells (mirVana RNA
extraction kit, Ambion), whole-genome transcriptional profil-
ing was performed using Illumina Human HT-12 V4 microar-
rays according to standard protocols [15]. Data retrieved from
the Illumina platform were background corrected, and quan-
tile normalized as previously described [16].
Statistical Analysis
A total of 5143 transcripts with detectable expression in at least
95% of all 96 study samples was used to calculate changes in
gene expression intensities occurring between the beginning
and the end of raltegravir-intensified (Δ1) or nonintensified
treatment intervals (Δ2) for each of the study participants
from groupA and B. Subsequently, gene transcripts that changed
significantly during Δ1 compared with Δ2 on a false discovery
rate (FDR)-adjusted P value < .05 were identified using 2-tailed
Student t tests and the Significant Analysis of Microarray pro-
gram (SAM) implemented in samr [17]. Functional annotations
of gene transcripts were analyzed using the Database for Anno-
tation, Visualization and Integrated Discovery (http://david.
abcc.ncifcrf.gov/). Correlations between gene expression intensity
and biological or immunological parameters were performed
by generalized estimated equations adjusted for repeated
measures.
Table 1. Clinical and Demographic Characteristics of Study
Participants
Study population N = 32 subjects
participating in ACTG 5244
Age (median, range) 52 (35–71) years
Sex (female/male ratio) 3 female, 29 male
Median plasma HIV-1 RNA (25%,








Prestudy ART regimen 11 Protease inhibitor-based
21 NNRTI-based
Race/ethnicity Black non-Hispanic: 7
Hispanic: 4
White non-Hispanic: 21
Abbreviations: ACTG, AIDS Clinical Trials Group; ART, antiretroviral therapy;
HIV, human immunodeficiency virus; NNRTI, nonnucleoside reverse-
transcriptase inhibitor.
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RESULTS
We observed a total of 121 gene transcripts with significant ex-
pression changes during raltegravir-intensified ART compared
with nonintensified ART. Compared with when participants
were receiving nonintensified ART, the expression intensity of
all of these transcripts increased during raltegravir intensification;
none decreased significantly (after FDR adjustment). Despite
reaching statistical significance, changes in expression intensity
for 79.3% of these transcripts were relatively small (<1.5 fold);
however, expression levels of 20.7% of these transcripts demon-
strated >1.5 fold changes during raltegravir intensification. Using
a hierarchical clustering approach, we observed that gene expres-
sion patterns of all 121 differentially expressed genes allowed us
to distinguish between intensified and the nonintensified treat-
ment periods in both study groups (Figure 1A; Supplementary
Table 1). Moreover, gene expression changes of these transcripts
during raltegravir-intensified and nonintensified therapy in treat-
ment group A closely resembled those observed in treatment
group B (Figure 1A and B), indicating that they were independent
of the relative timing of raltegravir intensification; however, dif-
ferences appeared to be slightly more pronounced in study group
B, which received raltegravir intensification in the second inter-
val. These data demonstrate that raltegravir intensification can be
associated with previously unrecognized, statistically significant
changes in host gene expression profiles of CD8+ T lymphocytes.
To understand the possible function of the gene transcripts
that are selectively upregulated during raltegravir intensification,
we analyzed their functional annotations (Figure 1B). We ob-
served that several of the raltegravir-responsive transcripts were
involved in glucose and carbohydrate metabolism, which can be
abnormally altered in persons infected with HIV-1 [18]. These
transcripts included PFKFB2 (which encodes 6-phosphofructo-
2-kinase/fructose-2,6-bisphosphatase 2); AMY1A (encoding for
alpha-amylase 1); B4GALT2 (encoding for beta-1,4-galactosyl-
transferase 2), which is known to be involved in the biosynthesis
of specific saccharide structures; SLC2A8, which encodes for
GLUT8, an intracellular glucose transporter [19]; and SSR2, en-
coding for components of the somatostatin receptor. Another set
of raltegravir-responsive gene transcripts plays important roles in
immune regulation and immune activation, parameters that are
independently associated with HIV-1 disease progression [20].
These genes included transcripts for the interleukin-6 receptor
and for the costimulatory molecule B7-H3 (CD276), which can
occur as a membrane-bound and soluble form and exerts con-
text-dependent inhibitory or activating immune signals [21].
Moreover, we noted elevated expression of the gene transcripts
encoding for DGK-zeta, a cell-intrinsic inhibitor of T-cell hyper-
activation [22], and for the junctional cell adhesion molecule
JAM-A, the lack of which has been associated with enhanced in-
testinal permeability, bacterial translocation, and immune activa-
tion [23]. It is interesting to note that AGGF1, which encodes a
factor that inhibits vascular inflammation [24], was also up-
regulated during raltegravir intensification, as was ROBO4, a
gene involved in stabilization of the vasculature and support of
angiogenesis [25]. Another group of upregulated transcripts
had known functions in regulating cell proliferation, gene tran-
scription, and tumor suppression; these transcripts included
MLL5, SENP5, WNK2, ZNF626, ZKSCAN1, TAF1C, PPBPL2,
EAPP, JTB, and STK11. We also observed transcriptional chang-
es in genes encoding for components of the cytoskeleton struc-
ture, the Golgi apparatus, and the endoplasmic reticulum, such as
TMED3, GOLGA8J, DERL3, TBCD, SPTA1, PLEC1, and BIN3.
Finally, transcripts encoding for proteins involved in calcium and
ion transport and metabolism were elevated during raltegravir in-
tensification; these included CALN1, FXYD4, ATP6V1E1, and
SLC30A9.
We subsequently studied the relative over- or underexpression
of specific genes during raltegravir-intensified ART by using gene
set enrichment analysis (GSEA), a computational method that is
independent of the detection of differentially expressed genes but
can identify more modest but coordinated changes in the expres-
sion levels of functionally related genes between 2 distinct study
populations [26].For these investigations, we selected 17 different
gene sets based on observations described in Figure 1A and B,
and we calculated enrichment scores for the respective transcripts
during treatment intervals with or without raltegravir intensifica-
tion using the GSEA algorithm [27] (Figure 1C; Supplementary
Table 2). Subsequently, these gene set enrichment scores were
each tested for statistical significance by a permutation test
with a test size of 1000, as described previously [27]. Overall,
these data demonstrated a significant enrichment of genes in-
volved in the HIV life cycle in nonraltegravir-intensified treat-
ment periods; transcripts within this group included RANBP2
[28], NUP214 [29], FEN1 [30], and several additional transcripts
that have recognized roles for supporting the efficacy of HIV-1
replication in human cells and were identified by high-through-
put functional genomic screens [31, 32]. In addition, there was a
trend for enrichment of transcripts involved in cell cycle regula-
tion during nonraltegravir-intensified treatment periods, whereas
genes encoding for components involved in transport and me-
tabolism of glucose and calcium were enriched during raltegra-
vir-intensified treatment periods (Figure 1C). Together, these
findings support our initial observation that raltegravir intensifi-
cation is associated with distinct transcriptional signatures of
genes with presumed roles in HIV-1 disease pathogenesis.
To further investigate the role of the 121 raltegravir-respon-
sive gene transcripts, we determined their association with im-
munologic or virologic characteristics of the study cohort. For
this purpose, we used generalized estimating equations adjusted
for repeated measures [33] implemented in geepack [34, 35] to
correlate the gene expression intensity of all analyzed 5143 tran-
scripts to the proportion of HLA-DR+/CD38+ CD4+ and CD8+
T cells, biomarkers of the viral reservoir size in ART-treated
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patients (total HIV-1 DNA, 2-LTR HIV-1 DNA) in CD4+ T
cells, and residual HIV-1 plasma RNA measured by single
copy assays; P values were adjusted for multiple comparisons
using the Benjamini-Hochberg FDR. Overall, using a linear
link function, we observed that 2 of the 121 raltegravir-respon-
sive transcripts were statistically associated with residual HIV-1
Figure 1. Differentially expressed gene transcripts in CD8 T cells during raltegravir-intensified antiretroviral therapy. A, Heatmap demonstrating the expres-
sion intensity of n = 121 gene transcripts with significantly (false discovery rate-corrected P < .05) different expression intensity during raltegravir intensified (Δ1)
vs nonraltegravir-intensified (Δ2) antiretroviral therapy. B, Expression changes of selected gene transcripts with differential expression during raltegravir inten-
sification. FC, fold change. C, Gene set enrichment scores of 17 predefined gene sets in raltegravir-intensified vs nonintensified treatment intervals.
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plasma viremia (LOC728440 and LOC654103); the precise bio-
logical function of these transcripts is currently unknown. We
identified an additional 339 transcripts that were statistically as-
sociated with 1 or more of the immunologic or virologic char-
acteristics of the study patients (residual HIV-1 plasma RNA:
n = 20 transcripts, proportion of HLA-DR+/CD38+ CD4+
T cells: n = 21 transcripts, proportion of HLA-DR+/CD38+
CD8+ T cells: n = 115 transcripts, CD4 T cell-associated total
HIV-1 DNA: n = 4 transcripts, CD4 T cell-associated 2-LTR
HIV-1 DNA (determined using a logit link function) n = 1 tran-
script); none of these transcripts were significantly affected by
raltegravir intensification (Figure 2; Supplementary Table 3).
DISCUSSION
In this study, we have identified a panel of gene transcripts in
CD8+ T cells that are significantly increased by intensification
of suppressive ART with raltegravir in a randomized clinical
trial in which no significant effects of raltegravir intensification
on biomarkers of the viral reservoir size or on the proportion
of activated lymphocytes were observed. Thus, these data demon-
strate more subtle, yet statistically significant effects of intensified
ART on host lymphocytes. Whether such transcriptional changes
in CD8+ T cells are clinically significant and relevant for deter-
mining disease outcome or disease progression will have to be in-
vestigated in future studies. Moreover, additional work will be
required to determine whether the observed changes of transcrip-
tional signatures indirectly result from the antiviral activities of
raltegravir or from direct pharmaceutical effects of raltegravir
on CD8+ T lymphocytes; HIV-1-negative individuals who receive
raltegravir as part of postexposure prophylaxis or pharmacokinet-
ic studies would be helpful to determine which of the observed
effects are due to direct effects of the drug on host cells as opposed
to changes related to the drug’s antiviral activity.
Functional annotations of raltegravir-responsive transcripts
found that treatment intensification mainly influenced genes re-
lated to carbohydrate metabolism, immune homeostasis, and
cell growth and proliferation, which are involved in immuno-
logical and metabolic abnormalities that are typically observed
in HIV-1 patients, even when viral replication is suppressed by
ART below the threshold of commercial PCR assays. As such,
raltegravir intensification may induce subtle and previously un-
recognized alterations of critical aspects of HIV-1 disease path-
ogenesis. However, our expression profiling experiments were
limited to CD8+ T cells, and they did not involve other cell sub-
sets such as endothelial cells, which may be affected by treat-
ment with raltegravir [36]. Therefore, functional studies in
additional cell subsets will be necessary to better define the pre-
cise consequences associated with raltegravir-associated gene
changes. Moreover, our study was not designed to analyze the
interplay between host gene expression profiles and the suscept-
ibility or resistance of CD4+ T cells to HIV-1 replication steps;
because the actual frequency of HIV-1-infected CD4+ T cells in
ART-treated patients is very low, such studies are better con-
ducted in ex vivo-infected CD4+ T cells [37].
CONCLUSIONS
Our data suggest that raltegravir intensification seems to have
previously unrecognized, significant effects on host genes that
may be functionally involved in specific aspects of HIV-1 disease
pathogenesis. In this way, this study highlights advantages of a
comprehensive, unbiased analysis approach for evaluation of bi-
ological effects of treatment interventions in clinical antiretroviral
treatment studies, and it may have implications for the future
evaluation and monitoring of antiretroviral treatment effects
that are independent from traditional outcome parameters.
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